Australia's most trusted
source of pharma news
Tuesday, 24 February 2026
Posted 24 February 2026 AM
Aussie oncolytic immunotherapy specialist ImmVirx has landed a second clinical collaboration, this time with BeOne Medicines.
The Phase 1 study, planned to commence in the second half of 2026, will assess ImmVirx’s investigational oncolytic RNA virus IVX055 in combination with BeOne’s PD-1 inhibitor Tevimbra for patients with "late-stage cancers".

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.